This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This NMT2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 125-153 amino acids from the C-terminal region of human NMT2.
NMT2
Reaktivität: Human
WB, IF (cc), IF (p)
Wirt: Kaninchen
Polyclonal
AbBy Fluor® 750
Applikationshinweise
For WB starting dilution is: 1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.5 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
NMT2
(N-Myristoyltransferase 2 (NMT2))
Andere Bezeichnung
NMT2
Hintergrund
N-myristoyltransferase (NMT) catalyzes the reaction of N-terminal myristoylation of many signaling proteins. It transfers myristic acid from myristoyl coenzyme A to the amino group of a protein's N-terminal glycine residue. Biochemical evidence indicates the presence of several distinct NMTs, varying in apparent molecular weight and /or subcellular distribution. The predicted 498-amino acid of human NMT2 protein shares 77 % and 96 % sequence identity with human NMT1 and mouse Nmt2 comprise two distinct families of N-myristoyltransferases.